Chapter 17: Second generation HPV vaccines to prevent cervical cancer

Area of Science:

• Vaccinology
• Virology
• Oncology

Background:

• Prophylactic human papillomavirus (HPV) vaccines utilizing non-infectious L1 virus-like particles (VLPs) are in advanced clinical trials.
• Previous research indicates these VLP-based vaccines are safe and highly effective in preventing HPV infections and cervical neoplasia.

Purpose of the Study:

• To evaluate the prospects for alternative HPV vaccine development.
• To address the need for second-generation vaccines given the anticipated availability of VLP vaccines.
• To assess potential candidates for clinical trials and their development pathways.

Main Methods:

• Review of clinical trial data for existing prophylactic HPV VLP vaccines.
• Analysis of the potential need and market for alternative HPV vaccine strategies.
• Assessment of candidate second-generation HPV vaccines for clinical development.

Main Results:

• Clinical trials demonstrate significant safety and efficacy of current HPV VLP vaccines.
• Widespread commercial availability of VLP vaccines is anticipated within years.
• The need for, candidates for, and commercialization path of alternative HPV vaccines require careful consideration.

Conclusions:

• Existing HPV VLP vaccines are safe and effective, nearing commercialization.
• The development of second-generation HPV vaccines must be weighed against the success of current VLP vaccines.
• Further evaluation is needed to determine the viability of alternative HPV vaccine candidates.